ijms-logo

Journal Browser

Journal Browser

Cancer-Related Biochemical Pathways: From Tumor Outgrowth, Metastasis to Novel Targeted Therapy

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (20 March 2025) | Viewed by 4562

Special Issue Editor


E-Mail Website
Guest Editor
Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy
Interests: biochemistry; oxidative stress; tumorigenesis; cell death pathway; resistance to anticancer therapies
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Despite the scientific achievements in the field of cancer prevention, disease management, and treatment of malignancy, the survival rates in most tumor types remain very poor. Dissecting biochemical pathways underlying the development of cancer should be given high priority to develop novel and effective therapeutic strategies. In this special issue, we invite investigators to contribute original research articles and review articles describing and discussing the various aspects of cancer-related biochemical pathways. We welcome new knowledge of the molecular alterations that deregulate signaling pathways and lead to tumor progression in human cancers. We would like to focus this Special Issue on studies that combine basic and translational research and provide deep knowledge of how a signaling pathway is involved in proliferation and/or different types of cancer cell death (apoptosis, ferroptosis, etc.). Particular focus will be done on the altered amino acid metabolism tightly linked to tumor outgrowth, metastasis, and therapeutic resistance.

Dr. Eleonora Vecchio
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • oncogenesis
  • novel targeted therapy
  • molecular mechanisms
  • drug resistance
  • cancer cell death
  • amino acid metabolism

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Jump to: Other

19 pages, 2532 KiB  
Review
WD Repeat and HMG Box DNA Binding Protein 1: An Oncoprotein at the Hub of Tumorigenesis and a Novel Therapeutic Target
by Zhiwei Zhang and Qing Zhu
Int. J. Mol. Sci. 2023, 24(15), 12494; https://doi.org/10.3390/ijms241512494 - 6 Aug 2023
Cited by 5 | Viewed by 2576
Abstract
WD repeat and HMG-box DNA binding protein 1 (WDHD1) is a highly conserved gene from yeast to humans. It actively participates in DNA replication, playing a crucial role in DNA damage repair and the cell cycle, contributing to centromere formation and sister chromosome [...] Read more.
WD repeat and HMG-box DNA binding protein 1 (WDHD1) is a highly conserved gene from yeast to humans. It actively participates in DNA replication, playing a crucial role in DNA damage repair and the cell cycle, contributing to centromere formation and sister chromosome segregation. Notably, several studies have implicated WDHD1 in the development and progression of diverse tumor types, including esophageal carcinoma, pulmonary carcinoma, and breast carcinoma. Additionally, the inhibitor of WDHD1 has been found to enhance radiation sensitivity, improve drug resistance, and significantly decrease tumor cell proliferation. This comprehensive review aims to provide an overview of the molecular structure, biological functions, and regulatory mechanisms of WDHD1 in tumors, thereby establishing a foundation for future investigations and potential clinical applications of WDHD1. Full article
Show Figures

Figure 1

Other

Jump to: Review

6 pages, 813 KiB  
Case Report
Precision Oncology Approach for Urachal Carcinoma: A Clinical Case Report
by Dániel Juhász, Anita Csizmarik, János Szalontai, Attila Keszthelyi, Bálint Dér, András Kubik, Miklós Szűcs, István Kenessey, Iris E. Ertl, Walter Berger, Bernhard Englinger, Shahrokh F. Shariat, Péter Nyirády and Tibor Szarvas
Int. J. Mol. Sci. 2024, 25(24), 13315; https://doi.org/10.3390/ijms252413315 - 12 Dec 2024
Cited by 1 | Viewed by 1210
Abstract
Urachal cancer (UrC) is a rare disease which is mostly diagnosed late due to symptoms caused by its local invasion to the urinary bladder. Given the lack of clinical trials and guideline recommendations for systemic treatment, a molecularly informed precision oncology approach is [...] Read more.
Urachal cancer (UrC) is a rare disease which is mostly diagnosed late due to symptoms caused by its local invasion to the urinary bladder. Given the lack of clinical trials and guideline recommendations for systemic treatment, a molecularly informed precision oncology approach is a viable option for UrC already in the early lines of systemic treatment. While single case experiences may provide valuable reference for later decision-making, well-documented clinical experience with off-label targeted treatments is limited to a few patients. Here, we report a case of a 31-year-old female UrC patient who underwent intensive therapy with three surgeries and five lines of systemic treatments, including chemo-, checkpoint inhibitor and tyrosine kinase inhibitor therapies. In addition, next-generation sequencing (NGS) analysis and an ex vivo drug-screening analysis were performed on patient-derived tumor cells and the results were implemented into the therapeutic decision-making. Finally, serum carcinoembryonic antigen (CEA) levels proved to be helpful for therapy monitoring during the whole follow-up period. Full article
Show Figures

Figure 1

Back to TopTop